Developing an mRNA–LNP vaccine to combat Lyme disease

Vaccine Insights 2023; 2(12), 4457–4460

DOI: 10.18609/vac.2023.61

Published: 20 December 2023
Matthew Pine

Lyme disease is the most common vector-borne disease in the US, but there is currently no vaccine to treat the nearly half a million people infected every year. Casey Nevins, Assistant Editor, Vaccine Insights, speaks with Matthew Pine, RNA Therapeutics Scientist, InVitro Cell Research, about how a misconception led to the withdrawal of the only human vaccine to date, and prospects for a new vaccine leveraging mRNA technology.